title: Therapeutic efficacy of combination of antitumor agent with AHC-52 against multidrug-resistant cells in the intravenously inoculated P388 leukemia model.
abstract: To predict the clinical effect on leukemic disease of a combination regimen developed to circumvent multidrug resistance (MDR), we tested various antitumor agents in the presence and absence of AHC-52, a sensitizing agent for multidrug-resistant cells, in the i.v.-i.v. model of murine leukemia. In this model system, sensitive and resistant P388 murine leukemia cells are inoculated i.v. into mice, and each antitumor agent is injected via the i.v. route. Vincristine (VCR) had no effect on the survival of mice bearing VCR-resistant P388, a relatively poorly resistant subline, when given either as a single agent or in combination with AHC-52. In contrast, adriamycin (ADR) alone had no effect on these mice, but its combination with AHC-52 resulted in significant survival, the maximal value achieved being 196% (treated mice/control animals, T/C). Etoposide (VP-16) strongly enhanced survival, even when used alone, and this effect was markedly potentiated by AHC-52. Combination of any antitumor drug with AHC-52 was ineffective in mice bearing ADR-resistant P388, a highly resistant subline. On the other hand, AHC-52 strongly augmented the therapeutic efficacy of these antitumor agents in mice bearing the sensitive parent P388 leukemia, producing some curative effects. On the basis of these results, the feasibility of this type of combination therapy is discussed.
authors.affiliation: Central Research Laboratories, Kyorin Pharmaceutical Co., Ltd., Tochigi, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Shinoda
authors.forename: H
authors.initials: H
authors.lastname: Ebisu
authors.forename: J
authors.initials: J
authors.lastname: Mitsuhashi
authors.forename: M
authors.initials: M
authors.lastname: Inaba
authors.forename: T
authors.initials: T
authors.lastname: Tsuruo
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004095:Dihydropyridines / Q000008:administration & dosage / Q000494:pharmacology*; D004317:Doxorubicin / Q000008:administration & dosage / Q000627:therapeutic use; D004351:Drug Resistance; D004357:Drug Synergism; D005047:Etoposide / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D007941:Leukemia P388 / Q000188:drug therapy* / Q000235:genetics; D051379:Mice; D008807:Mice, Inbred BALB C; D008811:Mice, Inbred DBA; D011720:Pyrazoles / Q000008:administration & dosage / Q000494:pharmacology*; D014750:Vincristine / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D004095:Dihydropyridines; D011720:Pyrazoles; C059017:AHC 52; D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin